Loading...
The anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (InO) provides high response rates in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). To explore its efficacy and safety in the frontline setting, investigators in Germany conducted an industry-supported prospective, multicenter, phase 2 trial in 45 patients older than 55 years with newly diagnosed Philadelphia chromosome–negative, CD22-expressing precursor-B-cell ALL.
Induction therapy included 2 or 3 cycles of InO plus dexamethasone, followed by age-adapted consolidation (5 cycles), late intensification (1 cycle), and maintenance chemotherapy (up to 2 years). Intrathecal chemotherapy prophylaxis was administered during all treatment phases. Serial measurable resi…